Calliditas Therapeutics AB ADR (CALT) Social Stream
CALLIDITAS THERAPEUTICS AB (CALT) Price Targets From Analysts
Use the tables below to see what analysts covering CALLIDITAS THERAPEUTICS AB think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
CALT's average price target has moved up $5.25 over the prior 39 weeks.
CALT reports an average of 177.5% for its upside potential over the past 39 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
CALT Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
CALT's average broker recommendation rating improved by 0 over the prior 30 weeks.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, CALLIDITAS THERAPEUTICS AB's variance in analysts' estimates is lower than 35.5% of them.
- To contextualize these metrics, consider that out of all US stocks, CALLIDITAS THERAPEUTICS AB's upside potential (average analyst target price relative to current price) is higher than 515.4% of them.
- In terms of how CALLIDITAS THERAPEUTICS AB fares relative to stocks in the small market cap category, note that its average analyst price target is higher than 550.53% of that group.
- In terms of how CALLIDITAS THERAPEUTICS AB fares relative to Healthcare stocks, note that its number of analysts covering the stock is greater than 109.82% of that group.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to CALLIDITAS THERAPEUTICS AB are CALA, BYSI, and BWV.
Is CALT a Buy, Hold or Sell? See the POWR Ratings now!